HeartFlow Secures 50th U.S. Patent
Patents Issued to Date Provide Broader Protection for Company’s FFRCT Technology REDWOOD CITY, Calif. – Oct. 7, 2015 – HeartFlow Inc., a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated, today announced that the United States Patent and Trademark Office has issued to HeartFlow its 50th patent. The patent, “Method and System […]
PLATFORM Trial Shows HeartFlow FFRCT Analysis Significantly Decreases Unnecessary Invasive Diagnostic Testing for Coronary Artery Disease
83% reduction in invasive tests showing no obstructive disease; revascularization rates unchanged LONDON – Sept. 1, 2015 – A technology developed by HeartFlow, Inc. has been shown to significantly reduce the use of invasive catheterization in patients with suspected coronary artery disease, according to a study presented today in a “Hot Line” session at the European Society of […]
HeartFlow Names New General Counsel to Executive Team
REDWOOD CITY, Calif. – Dec. 23, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has appointed Noemi C. (“Nicky”) Espinosa, as general counsel. Espinosa brings to HeartFlow 30 years of experience as both a business executive and outside counsel, representing medical device, life science and high tech companies. “Nicky’s extensive experience and […]
HeartFlow Appoints Former Johnson & Johnson Chairman and CEO William C. Weldon to Board of Directors
REDWOOD CITY, Calif. – Dec. 10, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has named William C. Weldon a new member of its board of directors. Weldon, who previously served as chairman and CEO of global healthcare products company Johnson & Johnson, joins the company’s board following the U.S. Food and […]
HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology
Highly Accurate, Non-invasive Test Has the Potential to Change the Way Coronary Artery Disease is Managed REDWOOD CITY, Calif. – Dec. 1, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, today announced that it received de novo clearance from the U.S. Food and Drug Administration for its FFRCT technology. HeartFlow FFRCT is the first […]
Landmark Study of HeartFlow’s New Non-Invasive Diagnostic Test Demonstrates High Diagnostic Performance in Patients with Suspected Coronary Artery Disease
Computed FFRCT Identifies Flow-Restricting Arterial Blockages with High Accuracy REDWOOD CITY AND SAN FRANCISCO, Calif., October 30, 2013 – HeartFlow, Inc. today announced positive data from a study of the company’s newest-generation non-invasive computed fractional flow reserve FFRCT technology. Results from the HeartFlowNXT study demonstrate that, when compared to standard coronary CT angiography (CT) or invasive coronary angiography (ICA), FFRCT provides […]
HeartFlow Receives 2011 EuroPCR Innovation Award
Annual Award Honors Technology With Greatest Potential to Change Practice of Interventional Medicine PARIS, May 20, 2011 – HeartFlow, Inc. announced today that the company has been honored with the 2011 EuroPCR Innovation Award for the company’s computed fractional flow reserve (FFRCT) technology, which is designed to provide data about blood flow within the arteries of […]
